A recent investigation has revealed that edibles marketed as “magic mushroom” products may not contain any of the expected psychoactive compound psilocybin. In addition, many of these products carry other active ingredients that were neither listed on their packaging nor subjected to sufficient safety evaluation.
Key Findings
- In Portland, Oregon, researchers collected 12 edible products—primarily gummies and one chocolate—that were advertised as containing psilocybin mushrooms.
- Laboratory analyses found no detectable psilocybin in any of the products.
- Instead, seven of the 12 products were found to include one or more undeclared active ingredients, such as:
- Cannabis extract, including THC, the principal psychoactive component in cannabis
- Caffeine
- Kava extract, an herbal substance with effects that are somewhat sedative or anxiety‐reducing in nature
- Four of the tested gummies contained no active ingredient of any kind.
- In two instances, the products contained synthetically produced psilocin (a compound related to psilocybin). However, because no other fungal compounds normally associated with natural psilocybin sources were found, the study authors concluded the psilocin was likely synthetic.
- Of particular concern, some gummies also contained synthetic psychedelic substances (“syndelics”) – in these cases, substances whose effects in humans are poorly understood or entirely unstudied.
Public Health Implications
- The mislabeling and presence of un-documented psychoactive substances pose clear risks. Regulatory bodies—including the U.S. Centers for Disease Control and Prevention—have previously noted severe adverse events after consumption of certain unregulated psilocybin‐labeled edibles.
- As interest in psychedelic therapies grows, so does the likelihood that consumers will seek products outside legally sanctioned channels. Products sold in informal or retail outlets may escape rigorous quality control.
Legal Landscape
- Under federal law in the United States, both psilocybin and psilocin are classified as Schedule I substances, meaning they are considered to have high abuse potential and no accepted medical use.
- Some states, however, have begun to permit regulated uses of these substances under specific conditions. For example:
- Colorado permits both medical and recreational use.
- New Mexico has passed a law legalizing certain medical uses.
- Oregon allows regulated psilocybin administration, but only via licensed service centers and licensed laboratories; sale or use outside those settings remains illegal.
Conclusions
The study serves as a strong warning: products marketed as containing magic mushrooms may not reliably contain psilocybin, and instead may include various psychoactive or active substances that are not disclosed, with unknown safety profiles. Consumers, regulators, and public health professionals are urged to approach these products with caution and to press for greater transparency and oversight in the marketplace.
Dabbin-Dad Newroom
